ArticleClinical rheumatology2025
Development and validation of predictive factors influencing rheumatoid arthritis associated with interstitial lung disease.
Article in Clinical rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Detection of rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis.BMC pulmonary medicine · 2026Pooled it
- A machine learning-based classification model for interstitial lung disease in rheumatoid arthritis.Frontiers in medicine · 2026Trial
- Development of a risk prediction model for rheumatoid arthritis-associated interstitial lung disease based on interpretable machine learning.Clinical rheumatology · 2026Article
- Review
- Current application, possibilities, and challenges of artificial intelligence in the management of rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis.Therapeutic advances in musculoskeletal disease · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
objectiveThis study is aimed at identifying key risk factors associated with the onset of rheumatoid arthritis-associated interstitial lung disease (RA-ILD) and developing and validating a novel risk prediction model for RA-ILD.
methodsThis is a hospital-based retrospective cohort study. A total of 459 RA patients were selected from Longhua Hospital Affiliated with Shanghai University of Traditional Chinese Medicine between 2015 and 2020 as observation subjects. Demographic and clinical data were collected through the hospital's medical record system. The analysis involved evaluating demographic factors, joint clinical characteristics, traditional Chinese medicine (TCM) syndrome classification, laboratory indicators, medication history, and their associations with RA-ILD. Subsequently, a machine learning model was applied to create and validate a novel risk prediction model for the onset of RA-ILD.
resultsThe overall frequency of RA-ILD was 42.70%. Advanced age, smoking, elevated rheumatoid DAS28 score, higher radiographic joint staging (Phases II and III), strong positive CCP status (above 200), and methotrexate therapy were identified as independent risk factors for RA-ILD. Conversely, hormone therapy was found to be a protective factor against RA-ILD development. The RA-ILD prediction model, formulated based on these risk factors, exhibited superior predictive performance compared to existing models, with an AUC of 0.8914 (95% CI 0.8593-0.9234), a sensitivity of 74.5%, and a specificity of 89.7%.
conclusionThe study results highlighted the risk factors for the onset of RA-ILD and underscored the utility of the established RA-ILD nomogram model for early identification of RA-ILD patients and predicting the future risk of RA-ILD in individuals with rheumatoid arthritis.
Indexed as
Identifiers
39724289What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.